NCT01496417View on ClinicalTrials.gov

Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

February 28, 2017

Study Completion Date

March 1, 2018

Conditions
End-Stage Renal Disease
Interventions
DRUG

Belatacept

Belatacept infusion intravenous at 10 mg/kg on post-operative days 1, 5, and weeks 2, 4, 8, 12; 5mg/kg intravenous dose at weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.

Trial Locations (1)

21201

University of Maryland, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Maryland

OTHER